한빛사논문
- 조회586
Chang Kyung Kang1†, Hyun Mu Shin2,3,4†, Pyoeng Gyun Choe1†, Jiyoung Park5, Jisu Hong2,3,5, Jung Seon Seo6, Yung Hie Lee6, Euijin Chang1,7, Nam Joong Kim1, Minji Kim2,3,8, Yong‑Woo Kim4, Hang‑Rae Kim2,3,4,8,9, Chang‑Han Lee2,3,5*, Jun‑Young Seo6*, Wan Beom Park1* and Myoung‑don Oh1
1Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, South Korea. 2Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, South Korea. 3BK21 FOUR Biomedical Science Project, Seoul National University College of Medicine, Seoul 03080, South Korea. 4Wide River Institute of Immunology, Seoul National University, Hongcheon 25159, South Korea. 5Department of Pharmacology, Seoul National University College of Medicine, Seoul 03080, South Korea. 6Severance Biomedical Science Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, South Korea. 7Department of Internal Medicine, Seoul Asan Medical Center, Seoul 05505, South Korea. 8Department of Anatomy & Cell Biology, Seoul National University College of Medicine, Seoul 03080, South Korea. 9Medical Research Institute, Seoul National University College of Medicine, Seoul 08030, South Korea.
†Chang Kyung Kang, Hyun Mu Shin, and Pyoeng Gyun Choe contributed equally to this work as the frst authors.
*Correspondence
Abstract
Background
Practical guidance is needed regarding the vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals in resource-limited countries. It includes the number of vaccine doses that should be given to unvaccinated patients who experienced COVID-19 early in the pandemic.
Methods
We recruited COVID-19 convalescent individuals who received one or two doses of an mRNA vaccine within 6 or around 18 months after a diagnosis of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. Their samples were assessed for IgG-binding or neutralizing activity and cell-mediated immune responses against SARS-CoV-2 wild-type and variants of concern.
Results
A total of 43 COVID-19 convalescent individuals were analyzed in the present study. The results showed that humoral and cellular immune responses against SARS-CoV-2 wild-type and variants of concern, including the Omicron variant, were comparable among patients vaccinated within 6 versus around 18 months. A second dose of vaccine did not significantly increase immune responses.
Conclusion
One dose of mRNA vaccine should be considered sufficient to elicit a broad immune response even around 18 months after a COVID-19 diagnosis.
논문정보
- Research article
- 2022년 05월 (BRIC 등록일 2022-05-19)
- 국내 연구진
- 생명과학 > 미생물학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
